# Artelo Biosciences (ARTL) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ARTL
## Company Profile
- Ticker: ARTL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 0.7513 USD
- Market cap: 5054033 USD
- Last updated: 2026-08-05
## Business Overview
### Lipid-Signaling Therapeutics
Artelo Biosciences develops medicines that modulate cannabinoid and fatty-acid signaling pathways. Its portfolio addresses cancer supportive care, pain and neuropsychiatric conditions through distinct small-molecule mechanisms.
### ART27.13
ART27.13 is a peripherally selective cannabinoid-receptor agonist in Phase 2 development for cancer anorexia-cachexia syndrome. The goal is to improve appetite, weight, lean body mass and activity without central psychoactive effects.
### ART26.12
ART26.12 is a fatty-acid-binding-protein 5 inhibitor being developed as a non-opioid, non-steroidal analgesic, initially for chemotherapy-induced peripheral neuropathy. A Phase 1 single-ascending-dose study showed favorable safety and predictable pharmacokinetics.
### ART12.11
ART12.11 is a proprietary cocrystal of cannabidiol and tetramethylpyrazine designed to improve the pharmaceutical properties of CBD. Preclinical work supports potential development in anxiety or depression-related indications.
## Why The Stock Is Moving

As of Aug 5, 2026, ARTL closed down 1.80% at $0.7513. No new same-company headline was identified in the current news window.

## Future Catalysts

- Opening of Phase 1 multiple-ascending-dose enrollment for ART26.12 planned in the third quarter of 2026.
- Toxicology results for ART12.11 expected in 2026.
- First-in-human ART12.11 study planned for the first half of 2027, subject to toxicology results.

## Drug Assets

- ART26.12

## Recent News
- 2026-07-22 12:39 EST — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432) — Source: Artelo Biosciences
- 2026-07-16 12:48 EST — [Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions](https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-results-from-a-nonclinical-osteoarthritis-study-sup-fa16911f) — Source: Artelo Biosciences
- 2026-07-14 12:47 EST — [Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026](https://biopharmsignal.com/news/ARTL/artelo-biosciences-issues-reminder-to-shareholders-to-vote-in-advance-of-annual--371c2cf4) — Source: Artelo Biosciences
- 2026-07-13 13:02 EST — [Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy](https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-positive-results-with-art27-13-in-a-nonclinical-mod-86480dfe) — Source: Artelo Biosciences
- 2026-07-01 12:42 EST — [Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury](https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-new-data-supporting-art26-12-as-a-potential-first-i-d595235b) — Source: Artelo Biosciences